Adam Lightfoot is Senior Lecturer in Physiology in the Department of Life Science at Manchester Metropolitan University. He was awarded a BSc (Hons) in Biomedical Sciences in 2006, and MRes in Jan Lotvall’s lab at Gothenberg University, in Cell Biology in 2007. Adam was awarded his PhD in 2011, examining the role of skeletal muscle as an endocrine organ, working with Anne McArdle and Richard Griffiths at the University of Liverpool.
Postdoctoral work followed with a Mersey Kidney First award, investigating mitochondrial dysfunction and skeletal muscle weakness in patients with chronic kidney disease (CKD). Adam was appointed Research Fellow in 2013, working alongside Bob Cooper, examining the cellular and molecular mechanisms of muscle weakness in patients with myositis, funded by Myositis UK.
Adam joined Manchester Met in 2016 as Lecturer, and continued research in myositis, with awards from The Royal Society & The Physiological Society, appointed Senior Lecturer in 2018. Adam took sabbatical in 2021, taking a role in Obesity at Novo Nordisk. Adam re-joined Manchester Met in January 2024 as Senior Lecturer in Physiology, leading an on-going research portfolio, in rare metabolic, mitochondrial diseases, obesity and ageing.
Adam has received in the region of ~£800k in competitive grant funding to-date, with awards from Myositis UK, The Myositis Association, The Royal Society & The Physiological Society. He has an array of
Adam Lightfoot is Senior Lecturer in Physiology in the Department of Life Science at Manchester Metropolitan University. He was awarded a BSc (Hons) in Biomedical Sciences in 2006, and MRes in Jan Lotvall’s lab at Gothenberg University, in Cell Biology in 2007. Adam was awarded his PhD in 2011, examining the role of skeletal muscle as an endocrine organ, working with Anne McArdle and Richard Griffiths at the University of Liverpool.
Postdoctoral work followed with a Mersey Kidney First award, investigating mitochondrial dysfunction and skeletal muscle weakness in patients with chronic kidney disease (CKD). Adam was appointed Research Fellow in 2013, working alongside Bob Cooper, examining the cellular and molecular mechanisms of muscle weakness in patients with myositis, funded by Myositis UK.
Adam joined Manchester Met in 2016 as Lecturer, and continued research in myositis, with awards from The Royal Society & The Physiological Society, appointed Senior Lecturer in 2018. Adam took sabbatical in 2021, taking a role in Obesity at Novo Nordisk. Adam re-joined Manchester Met in January 2024 as Senior Lecturer in Physiology, leading an on-going research portfolio, in rare metabolic, mitochondrial diseases, obesity and ageing.
Adam has received in the region of ~£800k in competitive grant funding to-date, with awards from Myositis UK, The Myositis Association, The Royal Society & The Physiological Society. He has an array of